Login to Your Account



Arena Defends New Phase III Data, Plans Lorcaserin Path

By Trista Morrison


Wednesday, November 10, 2010
Arena Pharmaceuticals Inc. released data from its Phase III BLOOM-DM trial of weight loss drug lorcaserin in obese and overweight diabetics on Tuesday, sparking plenty of debate among analysts and investors about whether the new findings would help – or hurt – the company's chances at addressing issues raised in an FDA complete response letter last month. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription